Clinical Trial Update: An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3) [Phase 1]

View source ↗

Summary

This Phase 1 open-label study evaluated the pharmacokinetics, safety, and tolerability of BI-RG-587 in combination with zidovudine in HIV-infected patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BI-RG-587
• Zidovudine (Zidovudine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections | Phase 1 | Status: COMPLETED